Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company's commercial portfolio includes ARIKAYCE (amikacin liposome inhalation suspension), an inhaled treatment for Mycobacterium avium complex (MAC) lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis. Beyond its approved products, Insmed is advancing a diverse clinical pipeline targeting pulmonary, immunology, inflammation, and rare neuromuscular conditions. Its early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, and RNA end-joining. Headquartered in Bridgewater, New Jersey, the company maintains a geographic footprint with operations and research facilities across the United States, Europe, and Japan.
